Michael Safi and Ashley Kirk report for us this morning: Revealed – big shortfall in Covax Covid vaccine-sharing scheme:
The global vaccine-sharing initiative Covax has so far delivered about one in five of the Oxford/AstraZeneca doses it estimated would arrive in countries by May, according to a Guardian analysis, starkly illustrating the cost of exports bans, hoarding and supply shortages on a scheme that represents a key lifeline for many in the developing world.
The organisations that run Covax had predicted that countries would receive fewer vaccines that expected after the Indian government restricted exports from its largest manufacturer in response to a catastrophic second wave there, but the figures reveal the shortfall to be severe, leaving many governments scrambling to secure doses elsewhere.
Large countries such as Indonesia and Brazil have so far received about one in 10 of the Oxford/AstraZeneca doses they were expecting by May, while Bangladesh, Mexico, Myanmar and Pakistan are among those that have not received any doses of the vaccine through the program so far.
A handful of countries such as Moldova, Tuvalu, Nauru and Dominica have received the full amount they were allocated, but the vast majority of those in the scheme have so far received a third or less of what they were allocated.
The shortage is leading to panic in countries such as Bangladesh, where a source in the vaccine industry said supplies of Oxford/AstraZeneca doses would run out within a fortnight, with no prospect of an imminent resupply.
“We have already given first doses to 5.7 million people and we have to give them the second dose, but we don’t have any supply,” he said, asking not to be named because he was not authorised to speak to media. “How do we immunise those 5.7 million people?”
Read more of Michael Safi and Ashley Kirk’s report: Revealed – big shortfall in Covax Covid vaccine-sharing scheme